Literature DB >> 15262848

Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism.

Masahiro Ito1, Takeshi Adachi, David R Pimentel, Yasuo Ido, Wilson S Colucci.   

Abstract

BACKGROUND: 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) inhibit myocyte hypertrophy in vitro and ameliorate the progression of cardiac remodeling in vivo, possibly because of inhibition of the small GTPase Rac1. The role of Rac1 in mediating myocyte apoptosis is not known. beta-Adrenergic receptor (betaAR)-stimulated myocyte apoptosis is mediated via activation of c-Jun NH2-terminal kinase (JNK), leading to activation of the mitochondrial death pathway. We hypothesized that betaAR-stimulated apoptosis in adult rat ventricular myocyte (ARVMs) is mediated by Rac1 and inhibited by statins. METHODS AND
RESULTS: betaAR stimulation increased apoptosis, as assessed by transferase-mediated nick-end labeling, from 5+/-1% to 24+/-2%. betaAR stimulation also increased Rac1 activity. Adenoviral overexpression of a dominant-negative mutant of Rac1 inhibited betaAR-stimulated apoptosis, JNK activation, cytochrome C release, and caspase-3 activation. Cerivastatin likewise inhibited the betaAR-stimulated activation of Rac1, decreased betaAR-stimulated apoptosis to 11+/-2%, and inhibited JNK activation, cytochrome C release, and caspase-3 activation.
CONCLUSIONS: betaAR stimulation causes Rac1 activation, which is required for myocyte apoptosis and leads to activation of JNK and the mitochondrial death pathway. Cerivastatin inhibits betaAR-stimulated activation of Rac1 and thereby inhibits JNK-dependent activation of the mitochondrial death pathway and apoptosis. The beneficial effects of statins on the myocardium may be mediated in part via inhibition of Rac1-dependent myocyte apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262848     DOI: 10.1161/01.CIR.0000136088.18960.E6

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

1.  Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation.

Authors:  Jin-Fu Xu; George R Washko; Kiichi Nakahira; Hiroto Hatabu; Avignat S Patel; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; James C Ross; Raúl San José Estépar; Alejandro A Diaz; Hui-Ping Li; Jie-Ming Qu; Blanca E Himes; Carolyn E Come; Katherine D'Aco; Fernando J Martinez; MeiLan K Han; David A Lynch; James D Crapo; Danielle Morse; Stefan W Ryter; Edwin K Silverman; Ivan O Rosas; Augustine M K Choi; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2012-01-12       Impact factor: 21.405

Review 2.  Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease.

Authors:  Miki Nagase; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2013-01-08       Impact factor: 28.314

3.  Pertussis toxin up-regulates angiotensin type 1 receptors through Toll-like receptor 4-mediated Rac activation.

Authors:  Motohiro Nishida; Reiko Suda; Yuichi Nagamatsu; Shihori Tanabe; Naoya Onohara; Michio Nakaya; Yasunori Kanaho; Takahiro Shibata; Koji Uchida; Hideki Sumimoto; Yoji Sato; Hitoshi Kurose
Journal:  J Biol Chem       Date:  2010-03-15       Impact factor: 5.157

Review 4.  HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.

Authors:  Ulrich Laufs; Florian Custodis; Michael Böhm
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Rac1 is required for cardiomyocyte apoptosis during hyperglycemia.

Authors:  E Shen; Yanwen Li; Ying Li; Limei Shan; Huaqing Zhu; Qingping Feng; J Malcolm O Arnold; Tianqing Peng
Journal:  Diabetes       Date:  2009-07-10       Impact factor: 9.461

Review 6.  The case for statin therapy in chronic heart failure.

Authors:  Pim van der Harst; Michael Böhm; Wiek H van Gilst; Dirk J van Veldhuisen
Journal:  Clin Res Cardiol       Date:  2007-12-01       Impact factor: 5.460

Review 7.  The role of statin therapy in the management of cardiomyopathies.

Authors:  Kumudha Ramasubbu; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2009-03       Impact factor: 5.113

Review 8.  Intervention for apoptosis in cardiomyopathy.

Authors:  Hiroyuki Yaoita; Yukio Maruyama
Journal:  Heart Fail Rev       Date:  2008-06       Impact factor: 4.214

9.  Mena associates with Rac1 and modulates connexin 43 remodeling in cardiomyocytes.

Authors:  Rashmi Ram; Andrew P Wescott; Katherine Varandas; Robert T Dirksen; Burns C Blaxall
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-01       Impact factor: 4.733

10.  Low density lipoproteins promote unstable calcium handling accompanied by reduced SERCA2 and connexin-40 expression in cardiomyocytes.

Authors:  Montserrat Barriga; Roi Cal; Nuria Cabello; Anna Llach; Alexander Vallmitjana; Raúl Benítez; Lina Badimon; Juan Cinca; Vicenta Llorente-Cortés; Leif Hove-Madsen
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.